Cardiff Oncology, Inc. Logo

Cardiff Oncology, Inc.

A clinical-stage biotech developing cancer therapies that inhibit Polo-like kinase 1.

CRDF | US

Overview

Corporate Details

ISIN(s):
US14147L1089
LEI:
Country:
United States of America
Address:
11055 FLINTKOTE AVENUE, 92121 SAN DIEGO

Description

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2023-02-09 17:50
FORM 3
English ZIP 6.9 KB
2023-02-09 10:23
JHG PLC OWNS <5%
English ZIP 12.0 KB
2023-02-02 17:02
8-K
English ZIP 189.9 KB
2023-01-26 14:30
CARDIFF ONCOLOGY, INC.
English ZIP 17.0 KB
2023-01-26 14:28
CARDIFF ONCOLOGY, INC.
English ZIP 17.1 KB
2022-11-29 17:11
FORM 4
English ZIP 6.7 KB
2022-11-03 17:14
8-K
English ZIP 138.4 KB
2022-11-03 17:00
10-Q
English ZIP 1.2 MB
2022-10-11 18:22
FORM 4
English ZIP 4.2 KB
2022-10-03 18:12
8-K
English ZIP 3.4 MB
2022-09-20 20:08
FORM 4
English ZIP 4.4 KB
2022-09-19 10:37
FORM 4
English ZIP 5.1 KB
2022-09-19 10:37
FORM 4
English ZIP 7.1 KB
2022-09-19 10:37
FORM 4
English ZIP 7.1 KB
2022-09-12 18:09
8-K
English ZIP 7.8 MB

Automate Your Workflow. Get a real-time feed of all Cardiff Oncology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cardiff Oncology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cardiff Oncology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adaptive Biotechnologies Corp Logo
Decodes the adaptive immune system to develop products for diagnosing and treating disease.
United States of America
ADPT
Adeia Inc. Logo
R&D company that licenses IP for the media, entertainment, and semiconductor industries.
United States of America
ADEA
Aditxt, Inc. Logo
Acquires, develops, and deploys health technologies to address major health challenges.
United States of America
ADTX
Advanced Biomed Inc. Logo
Develops microfluidic biochip diagnostic systems for precision oncology.
United States of America
ADVB
AIM ImmunoTech Inc. Logo
Immuno-pharma company developing therapeutics for oncology, immune, and viral diseases.
United States of America
AIM
Ainos, Inc. Logo
Develops AI-driven diagnostics, immune therapeutics, and telehealth POCT devices.
United States of America
AIMD
Akero Therapeutics, Inc. Logo
Clinical-stage company developing treatments for serious metabolic diseases like MASH.
United States of America
AKRO
Aladdin Healthcare Technologies SE Logo
Develops AI-powered tools for drug discovery and diagnostics for age-related conditions.
Germany
NMI
Alaunos Therapeutics, Inc. Logo
Clinical-stage immuno-oncology company developing TCR-T cell therapies for solid tumors.
United States of America
TCRT
Aligos Therapeutics, Inc. Logo
A clinical-stage biopharmaceutical company developing therapeutics for liver and viral diseases.
United States of America
ALGS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.